Evidence map›Paper›PMID 42110960›Full record

ReviewCardiac failure review2026

Comprehensive Management of Hyperkalaemia in Patients with Chronic Kidney Disease and Cardiovascular Conditions: Expert Recommendations from Mexico.

Antonio Méndez-Durán, Juan B Ivey-Miranda, Genaro H Mendoza-Zavala, Amada Álvarez-Sangabriel, Diana C Sánchez-Guerrero, Juan D Díaz-García, Julián A Borges-Vela, Luis E Morales-Buenrostro, Mateo Quilantán-Rodríguez, Ramón Ruíz-Mejía and 1 more

Abstract readReview
In one paragraph

Review in Cardiac failure review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Antonio Méndez-DuránInstituto Mexicano del Seguro Social Mexico City, Mexico.ORCID https://orcid.org/0000-0002-2596-4581
Juan B Ivey-MirandaHeart Failure Clinic, High Specialty Medical Unit, Hospital de Cardiología Centro Médico Nacional Siglo XXI Mexico City, Mexico.ORCID https://orcid.org/0000-0001-8800-7298
Genaro H Mendoza-ZavalaHeart Failure Clinic, High Specialty Medical Unit, Hospital de Cardiología Centro Médico Nacional Siglo XXI Mexico City, Mexico.ORCID https://orcid.org/0009-0009-1339-9683
Amada Álvarez-SangabrielHeart Failure Clinic, Instituto Nacional de Cardiología Ignacio Chávez Mexico City, Mexico.ORCID https://orcid.org/0000-0003-0593-2571
Diana C Sánchez-GuerreroDepartment of Haemodialysis and Transplantation, Christus Muguerza Alta Especialidad, Monterrey Nuevo León, Mexico.
Juan D Díaz-GarcíaNephrology and Transplantation Service, Internal Medicine and Nephrology Specialist, Hospital Clinic de Barcelona Barcelona, Spain.
Julián A Borges-VelaHeart Failure Clinic, Hospital Regional de Alta Especialidad de la Península de Yucatán Mérida, Yucatán, Mexico.
Luis E Morales-BuenrostroNephrology and Mineral Metabolism Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Mexico City, Mexico.
Mateo Quilantán-RodríguezHaemodialysis Service, Centro Medico Renal de Tamaulipas, Ciudad Madero Tamaulipas, Mexico.
Ramón Ruíz-MejíaNephrology Service, Centro Médico ISSEMYM Lic. Arturo Montiel Rojas Metepec Mexico State, Mexico.ORCID https://orcid.org/0000-0001-9953-1175
Sergio A Chávez-LealHospital SIMNSA Internacional, Tijuana Baja California, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with chronic kidney disease and/or cardiovascular disease are at heightened risk of developing hyperkalaemia. This electrolyte disorder is prevalent and, if left untreated, typically results in fatal outcomes. The implementation of standardised, specialised management strategies represents a valuable tool for clinicians in the care of these patients. The primary objective of this study is to present a consensus document for the management of hyperkalaemia of cardiorenal origin, developed by a group of experts in cardiology and nephrology, opinion leaders in Mexico. To this end, a Delphi panel was formed, comprising a group of cardiologists and a group of nephrologists, each coordinated by a leader who concentrated the information. The panellists responded to a questionnaire that was sent to them. In a virtual meeting, the responses were reviewed and a consensus was reached by all participants based on the current literature.

Indexed as

chronic kidney diseasediabetesheart failureHyperkalaemiarenin–angiotensin–aldosterone system inhibitortreatment

Identifiers

PMID42110960
PMCPMC13153925

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.